Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

4.72 -3.48

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.7

Max

4.85

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	2.2M -35M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+53.8% upside

Dividendes
By Acuity
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	26M 321M
Ouverture précédente	8.2
Clôture précédente	4.72

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 août 2026, 23:51 UTC

Correlated Moves

Bitcoin is trading lower, reflecting a cumulative decline since Friday. The asset is approximately 2.53% below its 20-day moving average.

1 août 2026, 23:01 UTC

The Nikkei 225 Index is trading lower during after-market hours, reflecting a decline from earlier highs and remaining near the lower end of its one-month range.

1 août 2026, 20:01 UTC

Oil (Brent) is trading higher in after-market hours, reflecting strong momentum and remaining above its 20-day moving average. No specific news was identified.

1 août 2026, 20:01 UTC

Correlated Moves

Silver is trading lower in after-market hours, reflecting weakness since Friday's close. The price is near the lower end of its one-month range.

1 août 2026, 20:01 UTC

The DAX 30 Index is trading lower in after-market hours, reversing earlier gains and closing below Friday's level. No specific news was identified.

1 août 2026, 20:01 UTC

Correlated Moves

Gold prices are lower during after-market hours, reflecting unusual price action near the lower end of its one-month range. Silver also declined in tandem.

1 août 2026, 19:11 UTC

Correlated Moves

Avalanche is trading lower during Saturday's session amid a broader cryptocurrency market downturn, with Bitcoin also declining and the asset below its 20-day moving average.

1 août 2026, 19:01 UTC

News

Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1 août 2026, 18:51 UTC

Cardano is trading higher during Saturday's session, reflecting a cumulative gain since Friday. The asset remains above its 20-day moving average.

1 août 2026, 18:41 UTC

Correlated Moves

Ethereum is trading lower today, influenced by declines in Bitcoin. The asset remains near the upper end of its one-month range.

1 août 2026, 18:01 UTC

The Nasdaq 100 Index is lower during after-market hours, declining since Friday's close and trading near the lower end of its one-month range.

1 août 2026, 11:52 UTC

Fed Chair Kevin Warsh's Upcoming Speech Sparks Market Speculation on Interest Rate Changes Amid Rising Inflation Concerns.

1 août 2026, 11:52 UTC

U.S. Nonfarm Productivity Expected to Rise 0.7% in Q2 2026 Amid Mixed Economic Signals

1 août 2026, 11:52 UTC

U.S. Unit Labour Costs Set to Rise 2.7% Amid Strong Wage Growth, Heightening Inflation Concerns Ahead of Federal Reserve Policy Decisions

1 août 2026, 11:51 UTC

Swiss markets closed for National Day; Bitcoin and Ethereum see slight gains, while concerns grow over U.S. stock market reliance on AI-driven stocks and potential Japanese Yen interventions.

1 août 2026, 11:51 UTC

"Bitcoin and Ethereum see gains amid speculation, while U.S. Dollar dips as traders eye key economic data and potential Fed policy shifts."

1 août 2026, 11:51 UTC

Bitcoin and Ethereum see modest gains amid economic uncertainties, while U.S. stock market concentration raises investor concerns and key labor data looms ahead.

1 août 2026, 11:51 UTC

Swiss markets closed for National Day; U.S. stocks rally amid inflation concerns and upcoming key labor data.

1 août 2026, 11:41 UTC

Mexico's Inflation Rate Release on August 7, 2026 Expected to Show Continued Easing Amid Global Trends.

1 août 2026, 11:41 UTC

U.S. Mortgage Rates Hit One-Year High at 6.66%, Raising Concerns Over Homebuying Demand Ahead of MBA Release on August 5

1 août 2026, 11:41 UTC

Mexico's Inflation Rate Release on August 7, 2026: Market Anticipates Impact on Economic Policy Amid Mixed Sentiment and External Risks.

1 août 2026, 11:31 UTC

U.S. Exports Data Release on August 4, 2026, Sparks Caution Amid Economic Slowdown and Global Trade Tensions

1 août 2026, 11:31 UTC

U.S. Trade Deficit Expected to Widen to -$73 Billion Amid Rising Imports and Geopolitical Tensions

1 août 2026, 11:22 UTC

U.S. Imports Data Release on August 4 Expected to Show Continued Growth Amid Tariff Distortions and Global Trade Dynamics

1 août 2026, 11:22 UTC

Canada's Balance of Trade expected to show C$3.0 billion surplus amid mixed economic sentiment and external challenges on August 4, 2026.

1 août 2026, 11:22 UTC

Market anticipates 75K job increase in upcoming ADP Employment Change report amid mixed economic signals and cautious optimism.

1 août 2026, 11:02 UTC

Japan's Upcoming Household Spending Report Signals Consumer Caution Amid Mixed Economic Indicators and Retail Disappointment.

1 août 2026, 11:02 UTC

Japan's Household Spending Expected to Rise 0.9% Amid Inflation Concerns and Yen Volatility Ahead of August Release

1 août 2026, 10:51 UTC

Brazil's Central Bank Faces Pressure on SELIC Rate Decision Amid Inflation and Economic Stability Concerns Ahead of August 5th Announcement.

1 août 2026, 10:51 UTC

Mexican Consumer Confidence Index Set for Release Amid Cautious Optimism and Mixed Economic Sentiment on August 4, 2026.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

53.8% hausse

Prévisions sur 12 Mois

Moyen 7.29 USD 53.8%

Haut 11 USD

Bas 4 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.